Founded in 2021 by Bing Yuan, Eric Slosberg, and Andy Fu, OnCusp Therapeutics is a Princeton-based clinical-stage biotech built around its founders’ global oncology development and partnering experience. The company advances promising preclinical research toward clinically validated cancer treatments, with its lead program CUSP06 now in clinical development for patients with advanced solid tumors.
FDA Fast Track Designation for CUSP06
Compliance program
Nuvation BioFounded in 2018 by biopharma veteran David Hung, M.D., Nuvation Bio develops and commercializes oncology medicines for difficult-to-treat cancers. The company’s portfolio includes the FDA-approved therapy IBTROZI® (taletrectinib) and investigational treatments supported by global clinical programs, with offices in the United States and China.New York, NY
NovocureNovocure grew from Professor Yoram Palti’s basement laboratory in Haifa, where he began exploring electric fields as a way to target cancer cells in 2000. Today, the international oncology company develops and commercializes Tumor Treating Fields therapy for patients facing some of the most aggressive solid tumors, while continuing research into wider applications.WAYNE, PA
Duo OncologyFounded by nanoparticle and drug-delivery researchers, Pittsburgh-based Duo Oncology is a clinical-stage biotechnology company developing tumor-activated medicines for cancer treatment. Its lead program, DUO-207, is designed to simplify chemotherapy by concentrating drug activity in tumors while reducing exposure in healthy tissue.PITTSBURGH, PA